Steroid induced osteoporosis: an opportunity for prevention?

I D Peat, S Healy, D M Reid, S H Ralston

Department of Medicine and Therapeutics, University of Aberdeen, United Kingdom.

OBJECTIVE--To determine the frequency with which osteoporosis prophylaxis is given to corticosteroid treated hospital inpatients. METHODS--All patients receiving systemic corticosteroids in a large teaching hospital over a three month period were identified through routine prescription monitoring by hospital ward pharmacists. Coprescription of antiosteoporotic therapy was recorded, along with other relevant details such as steroid dose, actual, or intended duration of therapy, and indication for therapy. RESULTS--Corticosteroids were prescribed to 214 patients over the study period, giving an average rate of 2.5 new prescriptions each day. Indications included: chest disease (n = 84; 39.2%), cancer (n = 17; 7.9%), inflammatory bowel disease (n = 16; 7.5%), rheumatoid arthritis/connective tissue disease (n = 16; 7.5%), and renal diseases (n = 7; 3.3%). One hundred and twelve patients (52.3%) were receiving short term steroid therapy (less than four months); 66 (37%) were receiving medium/long term steroid therapy (four months or more). In 36 cases (16.8%) the duration of therapy was unknown. Only 12 of the 214 patients (5.6%) received any form of osteoporosis prophylaxis. The prevalence of prophylaxis was similarly low in postmenopausal women (six of 93; 6.4%) and in patients receiving high dose long term steroid therapy (two of 25; 8%). CONCLUSIONS--Systemic corticosteroids are used frequently in hospital practice for a wide range of indications, but few patients receive co-prescription of prophylaxis against osteoporosis. This is true even in high risk groups such as postmenopausal women and those on high dose long term steroid therapy. Identification of individuals by the mechanism used in this study provides an opportunity by which all corticosteroid treated patients could be detected and offered osteoporosis prophylaxis before serious loss of bone density has occurred.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Wall, E., Walker-Bone, K. (2008). Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology. QJM 101: 317-323 [Abstract] [Full Text]  
• Liu, R. H., Albrecht, J., Werth, V. P. (2006). Cross-sectional Study of Bisphosphonate Use in Dermatology Patients Receiving Long-term Oral Corticosteroid Therapy. Arch Dermatol 142: 37-41 [Abstract] [Full Text]  
• Solomon, D. H., Morris, C., Cheng, H., Cabral, D., Katz, J. N., Finkelstein, J. S., Avorn, J. (2005). Medication Use Patterns for Osteoporosis: An Assessment of Guidelines, Treatment Rates, and Quality Improvement Interventions. Mayo Clin Proc. 80: 194-202 [Abstract]  
• Campbell, I A, Douglas, J G, Francis, R M, Prescott, R J, Reid, D M (2004). Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids. Thorax 59: 761-768 [Abstract] [Full Text]  
• Dolan, A L, Koshy, E, Waker, M, Goble, C M (2004). Access to bone densitometry increases general practitioners' prescribing for osteoporosis in steroid treated patients. Ann Rheum Dis 63: 183-186 [Abstract] [Full Text]  
• Gordon, M-M, Stevenson, S, Hunter, J A, Gudbjornsson, B, Juliusson, U I, Gudjonsson, F V (2002). Steroids cause osteoporosis. Ann Rheum Dis 61: 947-948 [Full Text]  
• Yeap, S. S., Hosking, D. J. (2002). Management of corticosteroid-induced osteoporosis. Rheumatology (Oxford) 41: 1088-1094 [Abstract] [Full Text]  
• Erb, N., Duncan, R. C., Raza, K., Rowe, I. F., Kitas, G. D., Situnayake, R. D. (2002). A regional audit of the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases in the West Midlands. Rheumatology (Oxford) 41: 1021-1024 [Abstract] [Full Text]  
• Gudbjornsson, B, Juliusson, U I, Gudjonsson, F V (2002). Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 61: 32-36 [Abstract] [Full Text]  
• Paget, S (2002). Steroids cause osteoporosis. Ann Rheum Dis 61 : 1-2 [Full Text]  
• de Nijs, R. N. J., Jacobs, J. W. G., Bijlsma, J. W. J., Lems, W. F., Laan, R. F. J. M., Houben, H. H. M., ter Borg, E. J., Huisman, A. M., Bruyn, G. A. W., van Oijen, P. L. M., Westgeest, A. A. A., Algra, A., Hofman, D. M. (2001). Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology (Oxford) 40: 1375-1383 [Abstract] [Full Text]  
• Yood, R. A., Harrold, L. R., Fish, L., Cernieux, J., Emani, S., Conboy, E., Gurwitz, J. H. (2001). Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting. Arch Intern Med 161: 1322-1327 [Abstract] [Full Text]  
• van Staa, T.P., Leufkens, H.G.M., Abenhaim, L., Begaud, B., Zhang, B., Cooper, C. (2000). Use of oral corticosteroids in the United Kingdom. QJM 93: 105-111 [Abstract] [Full Text]  
• COMPSTON, J E (1999). Management of bone disease in patients on long term glucocorticoid therapy. Gut 44: 770-772 [Full Text]  
• BIJLSMA, J. W J (1997). Prevention of glucocorticoid induced osteoporosis. Ann Rheum Dis 56: 507-509 [Full Text]